title: Season primes the brain in an arctic hibernator to facilitate entrance into torpor mediated by adenosine A(1) receptors.
abstract: Torpor in hibernating mammals defines the nadir in mammalian metabolic demand and body temperature that accommodates seasonal periods of reduced energy availability. The mechanism of metabolic suppression during torpor onset is unknown, although the CNS is a key regulator of torpor. Seasonal hibernators, such as the arctic ground squirrel (AGS), display torpor only during the winter, hibernation season. The seasonal character of hibernation thus provides a clue to its regulation. In the present study, we delivered adenosine receptor agonists and antagonists into the lateral ventricle of AGSs at different times of the year while monitoring the rate of O(2) consumption and core body temperature as indicators of torpor. The A(1) antagonist cyclopentyltheophylline reversed spontaneous entrance into torpor. The adenosine A(1) receptor agonist N(6)-cyclohexyladenosine (CHA) induced torpor in six of six AGSs tested during the mid-hibernation season, two of six AGSs tested early in the hibernation season, and none of the six AGSs tested during the summer, off-season. CHA-induced torpor within the hibernation season was specific to A(1)AR activation; the A(3)AR agonist 2-Cl-IB MECA failed to induce torpor, and the A(2a)R antagonist MSX-3 failed to reverse spontaneous onset of torpor. CHA-induced torpor was similar to spontaneous entrance into torpor. These results show that metabolic suppression during torpor onset is regulated within the CNS via A(1)AR activation and requires a seasonal switch in the sensitivity of purinergic signaling.
authors.affiliation: Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, Alaska 99775-7000, USA.
authors.forename: Tulasi R
authors.initials: TR
authors.lastname: Jinka
authors.forename: Øivind
authors.initials: Ø
authors.lastname: Tøien
authors.forename: Kelly L
authors.initials: KL
authors.lastname: Drew
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001110:Arctic Regions; D001831:Body Temperature / Q000187:drug effects / Q000502:physiology; D001833:Body Temperature Regulation / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D006605:Hibernation / Q000187:drug effects / Q000502:physiology*; D007276:Injections, Intraventricular / Q000379:methods; D010101:Oxygen Consumption / Q000187:drug effects / Q000502:physiology; D058914:Purinergic Antagonists / Q000494:pharmacology; D058906:Purinergic P1 Receptor Agonists / Q000494:pharmacology; D043682:Receptor, Adenosine A1 / Q000502:physiology*; D012589:Sciuridae / Q000502:physiology*; D012621:Seasons; D013686:Telemetry / Q000379:methods; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
chemical_list: C113602:MSX 3 compound; D058914:Purinergic Antagonists; D058906:Purinergic P1 Receptor Agonists; D043682:Receptor, Adenosine A1; D014970:Xanthines; C046756:5'-N-methylcarboxamideadenosine; C053907:8-cyclopentyl-1,3-dimethylxanthine; C027513:N(6)-cyclohexyladenosine; D013806:Theophylline; D000241:Adenosine